Bill Sponsor
BILLSPONSOR
Bill Sponsor
Politicians
Bills
Senate Bill 3942
116th Congress(2019-2020)
Securing America’s Medical Supply Chain and Advancing the Production of Life Saving Medicines Act
Introduced
Introduced
Introduced in Senate on Jun 11, 2020
Overview
Text
Introduced in Senate 
Jun 11, 2020
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Introduced in Senate(Jun 11, 2020)
Jun 11, 2020
Not Scanned for Linkage
About Linkage
Multiple bills can contain the same text. This could be an identical bill in the opposite chamber or a smaller bill with a section embedded in a larger bill.
Bill Sponsor regularly scans bill texts to find sections that are contained in other bill texts. When a matching section is found, the bills containing that section can be viewed by clicking "View Bills" within the bill text section.
Bill Sponsor is currently only finding exact word-for-word section matches. In a future release, partial matches will be included.
Jump To
S. 3942 (Introduced-in-Senate)


116th CONGRESS
2d Session
S. 3942


To establish the position of Chief Pharmaceutical and Medical Supply Chain Negotiator in the Office of the United States Trade Representative, to be responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, to advance domestic production of life-saving medicines, and to secure the United States medical supply chain to eliminate reliance on foreign governments, and for other purposes.

IN THE SENATE OF THE UNITED STATES

June 11, 2020

Mrs. Loeffler introduced the following bill; which was read twice and referred to the Committee on Finance

A BILL

To establish the position of Chief Pharmaceutical and Medical Supply Chain Negotiator in the Office of the United States Trade Representative, to be responsible for conducting trade negotiations and enforcing trade agreements related to acts, policies, and practices of foreign governments that fail to appropriately reward United States innovation with respect to pharmaceuticals, to advance domestic production of life-saving medicines, and to secure the United States medical supply chain to eliminate reliance on foreign governments, and for other purposes.

Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled,

SECTION 1. Short title.

This Act may be cited as the “Securing America’s Medical Supply Chain and Advancing the Production of Life Saving Medicines Act”.

SEC. 2. Chief Pharmaceutical and Medical Supply Chain Negotiator.

(a) In general.—Section 141 of the Trade Act of 1974 (19 U.S.C. 2171) is amended—

(1) in subsection (b)(2)—

(A) by striking “and one Chief Innovation and Intellectual Property Negotiator” and inserting “one Chief Innovation and Intellectual Property Negotiator, and one Chief Pharmaceutical and Medical Supply Chain Negotiator”;

(B) by striking “or the Chief Innovation and Intellectual Property Negotiator” and inserting “the Chief Innovation and Intellectual Property Negotiator, or the Chief Pharmaceutical and Medical Supply Chain Negotiator”; and

(C) by striking “and the Chief Innovation and Intellectual Property Negotiator” and inserting “the Chief Innovation and Intellectual Property Negotiator, and the Chief Pharmaceutical and Medical Supply Chain Negotiator”; and

(2) in subsection (c), by adding at the end the following new paragraph:

“(7) The principal function of the Chief Pharmaceutical and Medical Supply Chain Negotiator shall be to conduct trade negotiations and to enforce trade agreements relating to United States pharmaceutical products and services and medical supply chains. The Chief Pharmaceutical and Medical Supply Chain Negotiator shall be a vigorous advocate on behalf of United States pharmaceutical and medical supply chain interests. The Chief Pharmaceutical and Medical Supply Chain Negotiator shall perform such other functions as the United States Trade Representative may direct.”.

(b) Compensation.—Section 5314 of title 5, United States Code is amended by striking “Chief Innovation and Intellectual Property Negotiator, Office of the United States Trade Representative.” and inserting the following:

“ Chief Innovation and Intellectual Property Negotiator, Office of the United States Trade Representative.

“ Chief Pharmaceutical and Medical Supply Chain Negotiator, Office of the United States Trade Representative.”.

(c) Report required.—Not later than one year after the appointment of the first Chief Pharmaceutical and Medical Supply Chain Negotiator pursuant to paragraph (2) of section 141(b) of the Trade Act of 1974, as amended by subsection (a), and annually thereafter, the United States Trade Representative shall submit to the Committee on Finance of the Senate and the Committee on Ways and Means of the House of Representatives a report describing in detail—

(1) enforcement actions taken by the Trade Representative during the one-year period preceding the submission of the report to ensure the protection of United States pharmaceutical products and services and medical supply chains; and

(2) other actions taken by the Trade Representative to advance United States pharmaceutical products and services and medical supply chain interests.